Microtiter broth dilution method for yeast susceptibility testing with validation by clinical outcome
- 1 October 1986
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 24 (4) , 600-606
- https://doi.org/10.1128/jcm.24.4.600-606.1986
Abstract
There is no ideal laboratory procedure or culture medium in current use for susceptibility testing of pathogenic yeasts. Six candidate growth media (RPMI 1640 with L-glutamine, yeast nitrogen base, Casamino Acids medium, Mueller-Hinton broth, Sabouraud dextrose broth, and minimum essential medium-Eagle salts) were screened by spectromphotometric absorbance for nucleic acid and protein. From these, two media were selected: a chemically defined growth medium (RPMI 1640 with L-glutamine) and a chemically complex medium (Casamino Acids). MICs of four antifungal agents (5-fluorocytosine, micronazole, ketoconazole, and amphotericin B) for 84 clinical isolates of various Candida species were then determined with both media in agar dilution and microtiter broth dilution systems. The resultant MICs were correlated with clinical outcome for those isolates obtained from patients treated with single antifungal agents, and susceptiblity cut points were calculated. Derived MIC cut points for susceptibility were validated in a murine model of systemic candidiasis. RPMI 1640 with L-glutamine was found to have the lowest absorbance values for both nucleic acid and protein, while Casamino Acids medium was highest in both categories. We found that RPMI 1640 with L-glutamine was superior to Casamino Acids medium in the yield of MICs which correlated with actual clinical and animal outcome data. While there were no significant differences in MICs when RPMI 1640 medium was used, the microtiter broth dilution technique was superior to agar dilution in efficiency and ease of performance. We conclude that a microtiter broth system containing RPMI 1640 medium with L-glutamine is a simple, precise, and economical technique for susceptibility testing of pathogenic Candida species. We also suggest that the validation of susceptibility cut points with patient and animal outcome data make this microtiter broth system a preferential method for yeast susceptibility testing.This publication has 36 references indexed in Scilit:
- Combined Therapy with Amphotericin B and 5-Fluorocytosine for Candida MeningitisClinical Infectious Diseases, 1984
- Oral Candidiasis: Pathogenesis and Host DefenseClinical Infectious Diseases, 1984
- Correlation of in Vitro Susceptibility Test Results with in Vivo Response: Flucytosine Therapy in a Systemic Candidiasis ModelThe Journal of Infectious Diseases, 1983
- Neonatal systemic candidiasis: A failure to respond to intravenous miconazole in two neonatesArchives of Disease in Childhood, 1982
- Factors Influencing the Susceptibility of Candida albicans to the Polyenoic Antibiotics Nystatin and Amphotericin BJournal of General Microbiology, 1978
- MICONAZOLE-RESISTANT CANDIDAThe Lancet, 1978
- Effect of Culture Media on the Antifungal Activity of Miconazole and Amphotericin B Methyl EsterThe Journal of Infectious Diseases, 1976
- Laboratory tests of antifungal drugs.Journal of Clinical Pathology, 1975
- Fungistatic Activity, Uptake and Incorporation of 5-Fluorocytosine in Candida albicans, as Influenced by Pyrimidines and Purines. I. Reversal ExperimentsPathobiology, 1973
- Problems in the Diagnosis and Treatment of Systemic CandidiasisThe Journal of Infectious Diseases, 1972